

**RECEIVED
CENTRAL FAX CENTER**

JUN 24 2008

- 2 -

AMENDMENTS TO THE CLAIMS

1. (Previously Presented) An isolated human antibody, comprising:
human immunoglobulin VH-chain CDR1, CDR2, and CDR3 of a polypeptide consisting of amino-acid sequences represented by SEQ ID NOS: 4, 5, and 6, respectively; and
human immunoglobulin VL-chain CDR1, CDR2, and CDR3 of a polypeptide consisting of amino-acid sequences represented by SEQ ID NOS: 10, 11, and 12, respectively.
2. (Previously Presented) An isolated human antibody, comprising:
a polypeptide consisting of an amino-acid sequence represented by SEQ ID NO: 3;
and
a polypeptide consisting of an amino-acid sequence represented by SEQ ID NO: 9.
3. (Previously Presented) An isolated human antibody, comprising:
ligation of a polypeptide consisting of an amino-acid sequence represented by SEQ ID NO: 3 and
a polypeptide consisting of an amino-acid sequence represented by SEQ ID NO: 9.
4. (Cancelled)
5. (Cancelled)
6. (Cancelled)
7. (Currently Amended) An isolated ~~gene~~cDNA encoding a human antibody comprising:
human immunoglobulin VH-chain CDR1, CDR2, and CDR3 of a polypeptide consisting of amino-acid sequences represented by SEQ ID NOS: 4, 5, and 6, respectively; and
human immunoglobulin VL-chain CDR1, CDR2, and CDR3 of a peptide consisting of amino-acid sequences represented by SEQ ID NOS: 10, 11, and 12, respectively.

BOS2 680336.1

- 3 -

8. (Currently Amended) The genecDNA according to Claim 7, including as an open reading frame the nucleic acid sequence of SEQ ID NO: 1 or 7.

9. (Currently Amended) A recombinant expression vector, comprising the genecDNA according to Claim 7.

10. (Currently Amended) An isolated transformant, comprising the genecDNA according to Claim 7 introduced therein.

11. (Currently Amended) A method for producing a human antibody against human interleukin-18 by causing a host to express the genecDNA according to Claim 7.

12. (Currently Amended) A detector for human interleukin-18, the detector ~~using either (1)~~ comprising the antibody according to any one of Claims 1-3 or 37-39.

13. (Currently Amended) An immunological disease diagnostic kit for measuring an amount of human interleukin-18 contained in a test sample the human interleukin-18 antibody according to any one of claims 1-3 ~~or 37-39~~; and a carrier on which the human interleukin 18 antibody is immobilized.

14. (Currently Amended) A method for diagnosing immunological disease with increased IL-18 in accordance with an comprising: measuring the amount of human interleukin-18 contained in a test sample the amount of human interleukin-18 being measured by using a human antibody, comprising:

human immunoglobulin VH-chain CDR1, CDR2, and CDR3 of a polypeptide consisting of amino-acid sequences represented by SEQ ID NOS: 4, 5, and 6, respectively; and

human immunoglobulin VL-chain CDR1, CDR2, and CDR3 of a peptide consisting of amino-acid sequences represented by SEQ ID NOS: 10, 11, and 12, respectively.

15. (Cancelled)

BOS2 680336.1

- 4 -

16. (Previously Presented) A human interleukin-18 activity inhibitor comprising a human interleukin-18 antagonist as an active ingredient, the human interleukin-18 antagonist being the human antibody according to any one of claims 1-3 or 37-39.

17. (Cancelled)

18. (Cancelled)

19. (Cancelled)

20. (Cancelled)

21. (Cancelled)

22. (Cancelled)

23. (Cancelled)

24. (Cancelled)

25. (Currently Amended) A recombinant expression vector, comprising the gene cDNA according to Claim 8.

26. (Currently Amended) A transformant, comprising the gene cDNA according to Claim 8 introduced therein.

27. (Currently Amended) A method for producing a human antibody against human interleukin-18, comprising the steps of:

introducing the cDNA according to Claim 8 into a host; and

causing the host to express the cDNA thus expressed. ~~by causing a host to express the gene according to Claim 8, the human antibody being produced by the expression of the gene.~~

BOS2 680336.1

- 5 -

28. (Cancelled)

29. (Previously Presented) The human interleukin-18 activity inhibitor according to Claim 16, which is used for treating immunological disease.

30. (Canceled)

31. (Currently Amended) An isolated genecDNA encoding a human antibody, wherein the genecDNA encodes:

a polypeptide consisting of an amino-acid sequence represented by SEQ ID NO: 3;
and

a polypeptide consisting of an amino-acid sequence represented by SEQ ID NO: 9.

32. (genecDNA) An isolated genecDNA encoding a human antibody, wherein the genecDNA encodes:

ligation of a polypeptide consisting of an amino-acid sequence represented by SEQ ID NO: 3 a polypeptide consisting of an amino-acid sequence represented by SEQ ID NO: 9.

33. (Cancelled)

34. (Cancelled)

35. (Currently Amended) The method according to ~~any one of~~ claims 14, ~~33, or 34~~, wherein the antibody is a human antibody, being a human anti-human interleukin-18 antibody against human interleukin-18, the human antibody having (1) binding activity to human interleukin-18 and (2) inhibitory activity for inhibiting physiological activity of human interleukin-18.

36. (Currently Amended) The isolated genecDNA according to claim 7, wherein the genecDNA encodes a human antibody, being a human anti-human interleukin-18 antibody against human interleukin-18, the human antibody having (1) binding activity to human

BOS2 680336.1

- 6 -

interleukin-18 and (2) inhibitory activity for inhibiting physiological activity of human interleukin-18.

37. (Cancelled)

38. (Cancelled)

39. (Cancelled)

40. (Previously Presented) The human interleukin-18 activity inhibitor according to Claim 29, which inhibits cytokines produced from helper T1 cells stimulated with an antigen and human interleukin-18.

41. (Previously Presented) The human interleukin-18 activity inhibitor according to Claim 29, wherein the immunological disease is allergy or inflammation.

42. (Currently Amended) A method for diagnosing an immunological disease with increased IL-18 in accordance with an amount of human interleukin-18 contained in a test sample, the amount of human interleukin-18 being measured by using a human antibody, comprising:

a polypeptide consisting of an amino-acid sequence represented by SEQ ID NO: 3;
and

a polypeptide consisting of an amino-acid sequence represented by SEQ ID NO: 9.

43. (Currently Amended) A method for diagnosing an immunological disease with increased IL-18 in accordance with an amount of human interleukin-18 contained in a test sample, the amount of human interleukin-18 being measured by using a human antibody, comprising: a ligation of a polypeptide consisting of an amino-acid sequence represented by SEQ ID NO: 3 and a polypeptide consisting of an amino-acid sequence represented by SEQ ID NO: 9.

44. (New) The method of claim 14, wherein the immunological disease is atopic dermatitis, airway inflammation, airway hyperresponsiveness (AHR), or asthma.

BOS2 680336.1

- 7 -

45. (New) The method of claim 35, wherein the immunological disease is atopic dermatitis, airway inflammation, airway hyperresponsiveness (AHR), or asthma.

46. (New) The method of claim 42, wherein the immunological disease is atopic dermatitis, airway inflammation, airway hyperresponsiveness (AHR), or asthma.

47. (New) The method of claim 43, wherein the immunological disease is atopic dermatitis, airway inflammation, airway hyperresponsiveness (AHR), or asthma.

BOS2 680336.1